Skip to content

Stretch Mark Treatment · Aesthetic Medicine · Istanbul

Stretch Mark Treatment

Stretch marks, or striae distensae, change with time. Early red or violaceous striae and older pale striae differ in vascularity, pigment and structure; cause, skin type and anatomical area shape which options are reasonable.

Treatment may seek a partial change in colour or texture. Complete removal, restoration to previous skin or a permanent result is not promised.

Identity · composition · preparation · route

The treatment name is only the start of the medical description.

A responsible discussion identifies the exact preparation or device, how it was made, where it is intended to act and which clinical question is being assessed.

01Identity

What is it?

The intervention may be topical care, microneedling, radiofrequency, fractional laser or another device; each is a distinct product or energy system.

02Production

How is it prepared?

For topical products and devices, formulation, manufacturer, sterile consumables, energy delivery, maintenance and labelled use are checked separately.

03Route

How does it reach tissue?

Treatment may act at the surface or create controlled dermal injury; tissue depth and healing burden must be appropriate for the striae and skin type.

04Target

What is the clinical target?

The endpoint is a measured change in colour contrast, width or texture, not erasure or conversion to normal uninjured skin.

Striae treatment is stage- and skin-specific

Colour, maturity, width, depth and cause define the treatment question.

The intended role, product identity and target tissue stay visible so unlike procedures are not presented as one interchangeable class.

What Stretch Mark Treatment can do

  • Distinguish early coloured and mature pale striae
  • Assess cause, anatomical area and skin type
  • Select a limited colour or texture endpoint
  • Review healing and pigmentation before repetition

What Stretch Mark Treatment cannot do

  • Treat all stretch marks as the same stage
  • Guarantee complete removal or return to previous skin
  • Ignore pigmentation or scarring risk
  • Assume one device or topical product suits every area

Rapid new striae, unusual distribution or signs of an underlying medical or medicine-related cause may require diagnostic review before aesthetic treatment.

Clinical question before method selection

Five checks precede any personal decision.

Stage, width, colour, site, skin type, tanning, pregnancy context, medicines and previous reactions are reviewed before any method is considered.

  1. 01

    Stage the striae

    Early red or violaceous marks are separated from older pale, atrophic striae.

  2. 02

    Review the cause

    Growth, pregnancy, weight change, corticosteroid exposure and possible endocrine factors are considered.

  3. 03

    Assess skin and area

    Skin type, pigment history, sun exposure, thickness and anatomical site influence risk.

  4. 04

    Review healing factors

    Active skin disease, infection, keloid tendency, medicines and wound-healing history may exclude a procedure.

  5. 05

    Define a modest endpoint

    Colour contrast, texture or width is selected and compared with observation or no treatment.

Traceability without a public injection recipe

The method follows striae stage, skin type and target.

Vascular colour, pale atrophy and textural depth are not the same endpoint. Each device or topical route has a separate risk profile.

01Baseline

Stage and cause

Colour, maturity, width, site and clinical context are documented before treatment.

  • Differentiate early and mature striae
  • Review medical and medicine-related causes
  • Set one measurable endpoint
02Method

Product or device identity

The exact topical product, needle-based system, radiofrequency or laser is identified and matched to tissue.

  • Verify device and consumables
  • Match depth to target
  • Plan pigment and wound protection
03Review

Healing before repetition

Early reaction, pigment response and the later target are reviewed on separate timelines.

  • Document early skin response
  • Compare colour and texture later
  • Stop if risk outweighs signal

No topical formula, device setting, wavelength, energy, needle depth, pass count or personal treatment interval is provided here.

Read the data at product and indication level

Small trials compare methods, stages and endpoints that are not uniform.

Primary studies of microneedling, fractional laser and radiofrequency use different striae, skin types, scales and follow-up. No method removes striae completely.

01

Match the stage

A result in mature striae alba may not predict the response of early striae rubrae or vice versa.

02

Match skin type

Pigmentation outcomes and healing burden can differ across skin types and energy systems.

03

Read the endpoint

Observer-rated texture or colour change is not restoration of normal skin architecture.

04

Respect study size

Small split-area trials and short follow-up limit certainty about comparative benefit and recurrence.

Current evidence supports cautious, partial improvement in selected patients, not complete removal, superiority or a fixed course.

One indication · one traceable intervention · one review point

A plan chooses one striae stage and one endpoint.

Baseline photography, pigment risk, expected wound burden and alternatives are documented before a procedure is selected.

01

Address the context

Possible medical causes, active skin disease and recent body changes are reviewed first.

02

Choose colour or texture

The initial endpoint is limited rather than combining every visible feature into one promise.

03

Plan pigment protection

Sun exposure, tanning, aftercare and previous post-inflammatory pigment change shape timing.

04

Stop after poor healing

Blistering, prolonged redness, pigment change or scarring prevents routine escalation.

Expected reaction · adverse effect · clinical endpoint

Wound response and visible striae change need separate reviews.

Redness, swelling, pinpoint bleeding or crusting may follow some procedures; these reactions are not evidence of final benefit.

  1. 01Before treatment

    Set the baseline

    Stage, colour, width, texture and standardised photographs are recorded.

  2. 02Early safety

    Protect healing

    Blistering, increasing pain, discharge or spreading redness needs in-person assessment.

  3. 03Intermediate

    Review pigment

    Persistent redness, darkening or lightening is assessed before another treatment is considered.

  4. 04Decision

    Compare the endpoint

    Colour contrast or texture is reviewed after healing; no signal does not justify greater intensity automatically.

Material, anatomy and route shape risk

Pigment change and scarring must remain visible in the decision.

Risk varies with the selected method, intensity, anatomical site, striae stage, skin type and wound-healing history.

01Early

Procedure reaction

Pain, redness, swelling, pinpoint bleeding, crusting and temporary sensitivity may occur.

02Pigment

Pigment alteration

Post-inflammatory hyperpigmentation, hypopigmentation or prolonged redness may follow treatment.

03Serious

Tissue injury

Burn, infection, delayed healing, textural worsening or new scarring is possible.

04Urgency

Examine warning signs

Blisters, open areas, discharge, increasing pain or marked discolouration need early help.

Blistering, increasing pain, discharge, spreading inflammation or persistent marked pigment change requires in-person medical review before further treatment. Alternatives may include observation, camouflage, barrier-supportive skin care or acceptance of stable striae without a procedure.

A treatment decision must remain reviewable after travel

Assessment, product records and a local safety route travel together.

International care is not reduced to a treatment day. The in-person examination, exact intervention, early review and later endpoint are connected before departure.

01

Organise the question

History, previous procedures and the specific stretch mark treatment question prepare the visit without confirming suitability.

02

Examine in person

Anatomy, tissue, active disease, product or device status, risks and alternatives are reviewed together.

03

Keep exact records

Product or device identity, batch where relevant, treated region, route and observations remain traceable.

04

Arrange review

Expected reactions, stop criteria, local medical access and the later clinical endpoint are agreed before return travel.

Dr İsmail Aslan wearing a white medical coat
Dr İsmail AslanMedical DoctorClinical Focus: Hair Transplantation · Aesthetic Medicine

Product-specific, anatomy-led and reversible in decision-making

Stage and pigment risk come before device choice.

A realistic plan separates early and mature striae, names the limited endpoint and accepts that partial change may be the maximum defensible goal.

01

Stage first

Colour and maturity guide which evidence is relevant.

02

Review cause

A medical or medicine-related driver is not overlooked.

03

Protect pigment

Skin type and healing history shape method and timing.

04

Set a partial goal

Improvement is assessed without promising disappearance.

Medical responsibility: Dr İsmail AslanMedical review: 24 August 2026General patient information about stretch mark treatment; no personal protocol or outcome guarantee

Short and clear

Questions commonly asked before a decision.

These answers provide general orientation and do not replace personal diagnosis or treatment planning.

01Can stretch marks be removed completely?

No. Stretch marks are structural changes in the dermis. Depending on stage, skin type, region and method, colour contrast, width or surface texture may improve partly, but normal skin architecture cannot be restored. Invisible skin, a fixed percentage, a guaranteed number of sessions or permanent complete removal cannot responsibly be promised.

02What distinguishes striae rubrae from striae albae?

Striae rubrae are usually newer red-to-violet stretch marks with a more visible vascular and inflammatory component. Over time they may become paler, lighter and more atrophic; these are called striae albae. Colour, vascular component and tissue structure change the possible aim, so results or settings used for rubrae cannot automatically be transferred to albae.

03Can creams or oils reliably prevent or remove stretch marks?

There is no reliable general evidence that over-the-counter creams or oils safely prevent stretch marks or remove existing striae. Moisturising may ease dryness or tightness but does not automatically remodel the altered dermis. Medicinal topical agents need their own benefit–risk assessment, including pregnancy, breastfeeding, skin irritation and photosensitivity.

04When should stretch marks be medically assessed?

Unusually rapid spread, broad violet striae without a corresponding pregnancy, growth, weight or muscle phase, and additional symptoms may require medical assessment. All topical, inhaled, injected or systemic corticosteroids must also be disclosed. After a procedure, blisters, open areas, severe pain, fever, pus or pronounced skin discolouration require prompt local help.

Stage the striae · assess pigment risk · define a partial goal

Which feature of the stretch marks is realistic to assess?

The Online Pre-Assessment page can organise onset, cause and prior care. It cannot choose a device, setting or personal treatment sequence.